If you are wondering whether Vertex Pharmaceuticals' current share price gives you a fair entry point, this article will walk ...

Vertex has the revenue power to excel during any market environment.

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Vertex Pharmaceuticals is downgraded to Hold ahead of Q4 earnings due to underwhelming growth from key new drugs. Click for this earnings preview of VRTX stock.

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals. Looking at options history for Vertex Pharmaceuticals (NASDAQ:VRTX) we detected 11 trades. If we ...

Disappointing trial results for VX-993 led to a sell-off of Vertex's stock recently. The company's financials remain strong, and sales were up 12% last quarter. Vertex has been broadening its pipeline ...

Vertex, Inc. is rated a Buy due to steady growth, margin expansion, recurring revenue, and high retention. Learn more about ...

The market expects Vertex Pharmaceuticals (VRTX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known ...

Vertex stock has climbed more than 60% over three years.